Nestor F Gonzalez-Cadavid, PhD
Professor of Urology, David Geffen School of Medicine at UCLA
Professor of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Charles R. Drew University of Medicine and Science
Director, Urology Research Laboratory, LA BioMed at Harbor-UCLA Medical Center
Gene therapy of erectile dysfunction
Research DescriptionDr. Nestor Gonzalez-Cadavid has spent almost two decades studying the cellular and molecular pathophysiology of erectile dysfunction (ED), Peyronie’s disease, and diabetic nephropathy, all the while exploring potential biological and pharmacological therapies for these conditions. Dr. Gonzalez-Cadavid’s research on ED was inspired by the work carried out by co-investigator, Jacob Rajfer, M.D., who, in collaboration with Nobel Prize winner Louis Ignarro, discovered that nitric oxide is the mediator of penile erection.
Within this field of study, and as director of the Urology Research Laboratory, Dr. Gonzalez-Cadavid directs pioneering translational work on the concept that diffuse corporal tissue fibrosis and oxidative stress in the context of post-radical prostatectomy, aging, and diabetes are major factors for ED, similar to what occurs in a localized way, and as a result of other causes, in Peyronie’s disease. His lab work seeks to analyze stem cell therapy as a promising approach for ED that can be stimulated by concurrent pharmacological treatment.
Dr. Gonzalez-Cadavid is performing translational research to, a) determine whether exposure to the environmental contaminant BPA, released from plastics and acrylics, causes ED; b) analyze and assess the therapeutic use of muscle-derived stem cells (MDSC) for ED and limb ischemia in type 2 diabetes; and, c) assess the potential cancerous effects of excessive alcohol consumption on normal or malignant stem cells.
- MSc, 1961, University of Buenos Aires, Argentina
- PhD, 1964, University of Buenos Aires, Argentina
- PhD, 1967, University of London, England
Recent and/or Significant Publications
- Ferrini MG, Moon J, Rivera S, Rajfer J, Gonzalez-Cadavid NF. Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice. BJU Int. 2012 Feb;109(4):586-93. doi: 10.1111/j.1464-410X.2011.10397.x. Epub 2011 Aug 18.
- Toblli JE, Cao G, Giani JF, Angerosa M, Dominici FP, Gonzalez-Cadavid NF. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res. 2011;34(1):20-33. Epub 2010 Nov 11.
- Ferrini MG, Rivera S, Moon J, Vernet D, Rajfer J, Gonzalez-Cadavid NF. The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes. J Sex Med. 2010 Sep;7(9):3033-44. doi: 10.1111/j.1743-6109.2010.01884.x.